Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Sep 15, 2026, 10:26 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 470 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Conditions
Breast Cancer
Interventions
pegfilgrastim, carboplatin, docetaxel, conventional surgery
Biological · Drug · Procedure
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2005
U.S. locations
120
States / cities
Scottsdale, Arizona • Jacksonville, Florida • Aurora, Illinois + 78 more
Conditions
Cancer Survivor, Healthy Subject, Stage I Colorectal Cancer, Stage IA Breast Cancer, Stage IB Breast Cancer, Stage IIA Breast Cancer, Stage IIA Colorectal Cancer, Stage IIB Breast Cancer, Stage IIB Colorectal Cancer, Stage IIC Colorectal Cancer, Stage IIIA Breast Cancer, Stage IIIA Colorectal Cancer, Stage IIIB Breast Cancer, Stage IIIB Colorectal Cancer, Stage IIIC Breast Cancer, Stage IIIC Colorectal Cancer
Interventions
Educational Intervention, Internet-Based Intervention, Monitoring Device, Quality-of-Life Assessment, Questionnaire Administration
Other · Device
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
30 Years to 75 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
1
States / cities
Madison, Wisconsin
Conditions
Cancer Survivor, Stage 0 Breast Cancer, Stage IA Breast Cancer, Stage IB Breast Cancer, Stage IIA Breast Cancer, Stage IIB Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer
Interventions
Educational Intervention, Exercise Intervention, Quality-of-Life Assessment, Questionnaire Administration
Other · Behavioral
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
30 Years to 75 Years · Female only
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
1
States / cities
Columbus, Ohio
Conditions
Breast Cancer
Interventions
Soy protein isolate, Placebo
Dietary Supplement · Other
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older · Female only
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2003
U.S. locations
7
States / cities
Phoenix, Arizona • Tampa, Florida • Savannah, Georgia + 3 more
Conditions
Stage I Breast Cancer, Stage II Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer
Interventions
questionnaire administration, quality-of-life assessment, management of therapy complications, exercise intervention
Other · Procedure · Behavioral
Lead sponsor
University of Southern California
Other
Eligibility
18 Years and older · Female only
Enrollment
106 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
1
States / cities
Los Angeles, California
Conditions
Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage IA Breast Cancer AJCC v8, Anatomic Stage IB Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8, Anatomic Stage IIB Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8, Anatomic Stage IIIC Breast Cancer AJCC v8, Prognostic Stage I Breast Cancer AJCC v8, Prognostic Stage IA Breast Cancer AJCC v8, Prognostic Stage IB Breast Cancer AJCC v8, Prognostic Stage II Breast Cancer AJCC v8, Prognostic Stage IIA Breast Cancer AJCC v8, Prognostic Stage IIB Breast Cancer AJCC v8, Prognostic Stage III Breast Cancer AJCC v8, Prognostic Stage IIIA Breast Cancer AJCC v8, Prognostic Stage IIIB Breast Cancer AJCC v8, Prognostic Stage IIIC Breast Cancer AJCC v8
Interventions
Discussion, Exercise Intervention, Informational Intervention, Medical Device Usage and Evaluation, Quality-of-Life Assessment, Questionnaire Administration
Procedure · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
65 Years and older · Female only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
1
States / cities
Houston, Texas
Conditions
Cancer Survivor, Stage I Breast Cancer, Stage II Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer
Interventions
Educational Intervention
Other
Lead sponsor
City of Hope Medical Center
Other
Eligibility
21 Years and older · Female only
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Duarte, California
Conditions
Breast Cancer
Interventions
HER-2/neu peptide vaccine
Biological
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2003
U.S. locations
1
States / cities
Cleveland, Ohio
Conditions
Advanced Malignant Solid Neoplasm, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8, Anatomic Stage IIIC Breast Cancer AJCC v8, Estrogen Receptor Positive, HER2/Neu Negative, Metastatic Malignant Solid Neoplasm, Prognostic Stage III Breast Cancer AJCC v8, Prognostic Stage IIIA Breast Cancer AJCC v8, Prognostic Stage IIIB Breast Cancer AJCC v8, Prognostic Stage IIIC Breast Cancer AJCC v8, Recurrent Breast Carcinoma, TP53 wt Allele, Unresectable Malignant Solid Neoplasm
Interventions
MDM2/MDMX Inhibitor ALRN-6924, Paclitaxel
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
1
States / cities
Houston, Texas
Conditions
Breast Cancer
Interventions
carboplatin, paclitaxel albumin-stabilized nanoparticle formulation, vorinostat, placebo
Drug · Other
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older · Female only
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2027
U.S. locations
5
States / cities
Birmingham, Alabama • Indianapolis, Indiana • Annapolis, Maryland + 2 more
Conditions
Breast Cancer
Interventions
cyclophosphamide, Docetaxel, epirubicin hydrochloride, fluorouracil, ixabepilone
Drug
Lead sponsor
UNICANCER
Other
Eligibility
18 Years and older · Female only
Enrollment
762 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2020
U.S. locations
17
States / cities
Scottsdale, Arizona • Denver, Colorado • Jacksonville, Florida + 14 more
Conditions
Advanced Malignant Neoplasm, Castleman Disease, Digestive System Carcinoma, Erdheim-Chester Disease, Lip and Oral Cavity Carcinoma, Lymphangioleiomyomatosis, Malignant Endocrine Neoplasm, Malignant Female Reproductive System Neoplasm, Malignant Male Reproductive System Neoplasm, Malignant Neoplasm, Malignant Respiratory Tract Neoplasm, Malignant Thoracic Neoplasm, Malignant Urinary System Neoplasm, Mesothelial Neoplasm, Metastatic Malignant Neoplasm, Metastatic Urothelial Carcinoma, Neurofibromatosis Type 2, Recurrent Adult Soft Tissue Sarcoma, Recurrent Breast Carcinoma, Recurrent Childhood Soft Tissue Sarcoma, Recurrent Digestive System Carcinoma, Recurrent Female Reproductive System Carcinoma, Recurrent Male Reproductive System Carcinoma, Recurrent Malignant Neoplasm, Recurrent Pharyngeal Carcinoma, Recurrent Thyroid Gland Carcinoma, Refractory Malignant Neoplasm, Soft Tissue Neoplasm, Stage III Breast Cancer AJCC v7, Stage III Pharyngeal Cancer, Stage IIIA Breast Cancer AJCC v7, Stage IIIB Breast Cancer AJCC v7, Stage IIIC Breast Cancer AJCC v7, Stage IV Breast Cancer AJCC v6 and v7, Stage IV Pharyngeal Cancer, Stage IVA Pharyngeal Cancer, Stage IVB Pharyngeal Cancer, Stage IVC Pharyngeal Cancer, Thyroid Gland Neoplasm
Interventions
Bevacizumab, Cetuximab, Laboratory Biomarker Analysis, Pharmacological Study, Temsirolimus, Valproic Acid
Biological · Other · Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Not listed
Enrollment
154 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2026
U.S. locations
1
States / cities
Houston, Texas
Conditions
Breast Cancer
Interventions
bevacizumab, pegfilgrastim, cyclophosphamide, doxorubicin hydrochloride, paclitaxel albumin-stabilized nanoparticle formulation
Biological · Drug
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years and older · Female only
Enrollment
215 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
365
States / cities
Mobile, Alabama • Little Rock, Arkansas • Berkeley, California + 260 more
Conditions
Breast Cancer, Psychosocial Effects of Cancer and Its Treatment
Interventions
psychosocial assessment and care, quality-of-life assessment
Procedure
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
65 Years and older · Female only
Enrollment
1,706 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2016
U.S. locations
85
States / cities
Mountain View, California • Palo Alto, California • Pismo Beach, California + 66 more
Conditions
Cancer
Interventions
acyclovir, acyclovir sodium, valacyclovir
Drug
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
12 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2004
U.S. locations
6
States / cities
Duarte, California • Stanford, California • Omaha, Nebraska + 3 more
Conditions
Male Breast Carcinoma, Recurrent Breast Carcinoma, Stage IIIC Breast Cancer AJCC v7, Stage IV Breast Cancer AJCC v6 and v7, Triple-Negative Breast Carcinoma
Interventions
Azacitidine, Entinostat, Laboratory Biomarker Analysis, Pharmacological Study
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2023
U.S. locations
7
States / cities
Duarte, California • Los Angeles, California • Sacramento, California + 4 more
Conditions
Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage IA Breast Cancer AJCC v8, Anatomic Stage IB Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8, Anatomic Stage IIB Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8, Anatomic Stage IIIC Breast Cancer AJCC v8, Lung Non-Small Cell Carcinoma, Prognostic Stage I Breast Cancer AJCC v8, Prognostic Stage IA Breast Cancer AJCC v8, Prognostic Stage IB Breast Cancer AJCC v8, Prognostic Stage II Breast Cancer AJCC v8, Prognostic Stage IIA Breast Cancer AJCC v8, Prognostic Stage IIB Breast Cancer AJCC v8, Prognostic Stage III Breast Cancer AJCC v8, Prognostic Stage IIIA Breast Cancer AJCC v8, Prognostic Stage IIIB Breast Cancer AJCC v8, Prognostic Stage IIIC Breast Cancer AJCC v8, Stage I Lung Cancer AJCC v8, Stage IA1 Lung Cancer AJCC v8, Stage IA2 Lung Cancer AJCC v8, Stage IA3 Lung Cancer AJCC v8, Stage IB Lung Cancer AJCC v8, Stage II Lung Cancer AJCC v8, Stage IIA Lung Cancer AJCC v8, Stage IIB Lung Cancer AJCC v8, Stage III Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Stage IIIB Lung Cancer AJCC v8, Stage IIIC Lung Cancer AJCC v8
Interventions
Cognitive Behavior Therapy, Interview, Quality-of-Life Assessment, Questionnaire Administration
Behavioral · Other
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Los Angeles, California
Conditions
Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage IA Breast Cancer AJCC v8, Anatomic Stage IB Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8, Anatomic Stage IIB Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8, Anatomic Stage IIIC Breast Cancer AJCC v8, Localized Breast Carcinoma, Prognostic Stage I Breast Cancer AJCC v8, Prognostic Stage IA Breast Cancer AJCC v8, Prognostic Stage IB Breast Cancer AJCC v8, Prognostic Stage II Breast Cancer AJCC v8, Prognostic Stage IIA Breast Cancer AJCC v8, Prognostic Stage IIB Breast Cancer AJCC v8, Prognostic Stage III Breast Cancer AJCC v8, Prognostic Stage IIIA Breast Cancer AJCC v8, Prognostic Stage IIIB Breast Cancer AJCC v8, Prognostic Stage IIIC Breast Cancer AJCC v8, Triple-Negative Breast Carcinoma, Metastatic Breast Cancer
Interventions
Best Practice, Informational Intervention, Medical Device Usage and Evaluation, Quality-of-Life Assessment, Survey Administration
Other
Lead sponsor
Emory University
Other
Eligibility
18 Years and older · Female only
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
4
States / cities
Atlanta, Georgia
Conditions
Advanced Breast Carcinoma, Advanced Endometrial Carcinoma, Advanced Fallopian Tube Carcinoma, Advanced Hepatocellular Carcinoma, Advanced Malignant Abdominal Neoplasm, Advanced Malignant Female Reproductive System Neoplasm, Advanced Malignant Thoracic Neoplasm, Advanced Ovarian Carcinoma, Advanced Primary Peritoneal Carcinoma, Advanced Renal Cell Carcinoma, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8, Anatomic Stage IIIC Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Malignant Abdominal Neoplasm, Malignant Solid Neoplasm, Metastatic Breast Carcinoma, Metastatic Endometrial Carcinoma, Metastatic Fallopian Tube Carcinoma, Metastatic Hepatocellular Carcinoma, Metastatic Malignant Abdominal Neoplasm, Metastatic Malignant Female Reproductive System Neoplasm, Metastatic Malignant Thoracic Neoplasm, Metastatic Ovarian Carcinoma, Metastatic Primary Peritoneal Carcinoma, Metastatic Renal Cell Carcinoma, Prognostic Stage III Breast Cancer AJCC v8, Prognostic Stage IIIA Breast Cancer AJCC v8, Prognostic Stage IIIB Breast Cancer AJCC v8, Prognostic Stage IIIC Breast Cancer AJCC v8, Prognostic Stage IV Breast Cancer AJCC v8, Stage III Fallopian Tube Cancer AJCC v8, Stage III Hepatocellular Carcinoma AJCC v8, Stage III Ovarian Cancer AJCC v8, Stage III Primary Peritoneal Cancer AJCC v8, Stage III Renal Cell Cancer AJCC v8, Stage III Uterine Corpus Cancer AJCC v8, Stage IIIA Fallopian Tube Cancer AJCC v8, Stage IIIA Hepatocellular Carcinoma AJCC v8, Stage IIIA Ovarian Cancer AJCC v8, Stage IIIA Primary Peritoneal Cancer AJCC v8, Stage IIIA Uterine Corpus Cancer AJCC v8, Stage IIIA1 Fallopian Tube Cancer AJCC v8, Stage IIIA1 Ovarian Cancer AJCC v8, Stage IIIA2 Fallopian Tube Cancer AJCC v8, Stage IIIA2 Ovarian Cancer AJCC v8, Stage IIIB Fallopian Tube Cancer AJCC v8, Stage IIIB Hepatocellular Carcinoma AJCC v8, Stage IIIB Ovarian Cancer AJCC v8, Stage IIIB Primary Peritoneal Cancer AJCC v8, Stage IIIB Uterine Corpus Cancer AJCC v8, Stage IIIC Fallopian Tube Cancer AJCC v8, Stage IIIC Ovarian Cancer AJCC v8, Stage IIIC Primary Peritoneal Cancer AJCC v8, Stage IIIC Uterine Corpus Cancer AJCC v8, Stage IIIC1 Uterine Corpus Cancer AJCC v8, Stage IIIC2 Uterine Corpus Cancer AJCC v8, Stage IV Fallopian Tube Cancer AJCC v8, Stage IV Hepatocellular Carcinoma AJCC v8, Stage IV Ovarian Cancer AJCC v8, Stage IV Primary Peritoneal Cancer AJCC v8, Stage IV Renal Cell Cancer AJCC v8, Stage IV Uterine Corpus Cancer AJCC v8, Stage IVA Fallopian Tube Cancer AJCC v8, Stage IVA Hepatocellular Carcinoma AJCC v8, Stage IVA Ovarian Cancer AJCC v8, Stage IVA Primary Peritoneal Cancer AJCC v8, Stage IVA Uterine Corpus Cancer AJCC v8, Stage IVB Fallopian Tube Cancer AJCC v8, Stage IVB Hepatocellular Carcinoma AJCC v8, Stage IVB Ovarian Cancer AJCC v8, Stage IVB Primary Peritoneal Cancer AJCC v8, Stage IVB Uterine Corpus Cancer AJCC v8
Interventions
Atezolizumab, Cabozantinib S-malate, Nab-paclitaxel, Tumor Treating Fields Therapy
Biological · Drug · Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Houston, Texas
Conditions
Recurrent Breast Cancer, Stage IA Breast Cancer, Stage IB Breast Cancer, Stage II Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer
Interventions
omega-3 fatty acid supplement, Placebo, Clinical assessments, Assessment of therapy complications, Magnetic Resonance Imaging, Correlative/special studies
Dietary Supplement · Other · Procedure
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Columbus, Ohio
Conditions
Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage IA Breast Cancer AJCC v8, Anatomic Stage IB Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8, Anatomic Stage IIB Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8, Anatomic Stage IIIC Breast Cancer AJCC v8, Cancer Survivor, Obesity, Overweight, Prognostic Stage I Breast Cancer AJCC v8, Prognostic Stage IA Breast Cancer AJCC v8, Prognostic Stage IB Breast Cancer AJCC v8, Prognostic Stage II Breast Cancer AJCC v8, Prognostic Stage IIA Breast Cancer AJCC v8, Prognostic Stage IIB Breast Cancer AJCC v8, Prognostic Stage III Breast Cancer AJCC v8, Prognostic Stage IIIA Breast Cancer AJCC v8, Prognostic Stage IIIB Breast Cancer AJCC v8, Prognostic Stage IIIC Breast Cancer AJCC v8
Interventions
Aerobic Exercise, Exercise Counseling, Nutritional Assessment, Quality-of-Life Assessment, Questionnaire Administration, Resistance Training
Other
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
30 Years to 75 Years · Female only
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Columbus, Ohio
Conditions
HER2 Positive Breast Carcinoma, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer
Interventions
Copper Cu 64-DOTA-Trastuzumab, Laboratory Biomarker Analysis, Pertuzumab, Positron Emission Tomography, Therapeutic Conventional Surgery, Trastuzumab
Radiation · Other · Biological + 1 more
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older · Female only
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2026
U.S. locations
1
States / cities
Duarte, California
Conditions
Anatomic Stage 0 Breast Cancer AJCC v8, Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage IA Breast Cancer AJCC v8, Anatomic Stage IB Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8, Anatomic Stage IIB Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8, Anatomic Stage IIIC Breast Cancer AJCC v8, Prognostic Stage 0 Breast Cancer AJCC v8, Prognostic Stage I Breast Cancer AJCC v8, Prognostic Stage IA Breast Cancer AJCC v8, Prognostic Stage IB Breast Cancer AJCC v8, Prognostic Stage II Breast Cancer AJCC v8, Prognostic Stage IIA Breast Cancer AJCC v8, Prognostic Stage IIB Breast Cancer AJCC v8, Prognostic Stage III Breast Cancer AJCC v8, Prognostic Stage IIIA Breast Cancer AJCC v8, Prognostic Stage IIIB Breast Cancer AJCC v8, Prognostic Stage IIIC Breast Cancer AJCC v8
Interventions
Behavioral, Psychological or Informational Intervention, Best Practice, Quality-of-Life Assessment, Questionnaire Administration
Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
256 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
1
States / cities
Houston, Texas
Conditions
Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage IA Breast Cancer AJCC v8, Anatomic Stage IB Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8, Anatomic Stage IIB Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8, Anatomic Stage IIIC Breast Cancer AJCC v8, Premenopausal, Prognostic Stage I Breast Cancer AJCC v8, Prognostic Stage IA Breast Cancer AJCC v8, Prognostic Stage IB Breast Cancer AJCC v8, Prognostic Stage II Breast Cancer AJCC v8, Prognostic Stage IIA Breast Cancer AJCC v8, Prognostic Stage IIB Breast Cancer AJCC v8, Prognostic Stage III Breast Cancer AJCC v8, Prognostic Stage IIIA Breast Cancer AJCC v8, Prognostic Stage IIIB Breast Cancer AJCC v8, Prognostic Stage IIIC Breast Cancer AJCC v8
Interventions
Adenosine, Magnetic Resonance Imaging, Regadenoson, Stress Management Therapy
Biological · Procedure · Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
Up to 55 Years · Female only
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Winston-Salem, North Carolina